Updates in the Treatment of Relapsed or Refractory Marginal Zone Lymphoma
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Palbociclib Plus Trastuzumab, With/Without Pertuzumab, and ET as Maintenance in HR+, HER2+ Metastatic Breast Cancer
2
Allogeneic BCMA CAR T-Cell Therapy CT0596 Elicits 100% ORR in R/R Myeloma and Plasma Cell Leukemia
3
Tirabrutinib May Shift the R/R PCNSL Treatment Paradigm Toward Improved Tolerability
4
Dr Myre on a Phase 1 Study of SYNC-T SV-102 in Prostate Cancer
5